Some highlights of the 2017 French Society of Hematology meeting are summarised. The T-cell lymphoma most frequent, angioimmunoblastic lymphoma is now recognised as derived from follicular helper T-cells. No major advancement in the treatment of T-cell lymphoma has been obtained. However many new drugs are promising, especially Brentuximab Vedotin for CD30 lymphoma. Two publications were presented as favourites (coup de cœur): phase III in primary CNS lymphoma and long term results of CLL8 trial. Two major publications from the LYSA group were reported: the Lyma trial in MCL demonstrated efficacy of rituximab maintenance and the Remarc trial showed efficacy of lenalidomide after R-CHOP in DLBCL to prolong DFS.

(BELG J HEMATOL 2017;8(5):201–2)